Immutep Lung Cancer Drug Achieves Excellent Initial Overall Survival Benefit
Australian biotechnology company, Immutep Limited (NASDAQ: IMMP) has announced that an immuno-oncology combination of eftilagimod alpha (efti) and KEYTRUDA® (pembrolizumab) has generated meaningful long-term survival in 1st line non-small cell lung cancer (NSCLC) patients in a Phase 2 clinical trial.
Efti was granted FDA Fast Track designation for the treatment of NSCLC in October 2022 and is under evaluation for a variety of solid tumours including head and neck squamous cell carcinoma and metastatic breast cancer.
Immutep’s investigational combination, without the use of chemotherapy, led to excellent initial survival results in the overall intent-to-treat (ITT) 1L NSCLC patient population, regardless of PD-L1 expression status.
Safety and efficacy data from the trial offers compelling evidence of efti’s substantial impact in safely stimulating patients immune responses to fight cancer.
Lung cancer is the second most common cancer and NSCLC accounts for approximately 80-85% of all lung cancers, impacting an estimated 1.87 million people annually.
Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximize value for shareholders.